PFO

PFD, PFO, FFC, FLC and DFP Announce February, March and April Dividends

Retrieved on: 
Friday, January 19, 2024
Professional Services, Finance, DFP, FFC, Ó Flaithbheartaigh, PFD, FLC, PFO, Security (finance)

An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.

Key Points: 
  • An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.
  • A distribution rate that is largely comprised of sources other than income may not be reflective of a fund’s performance.
  • FLC invests primarily in preferred and other income-producing securities with a primary investment objective of high current income and a secondary objective of capital appreciation.
  • DFP invests primarily in preferred and other income-producing securities with an investment objective of total return, with an emphasis on high current income.

PFD, PFO, FFC, FLC and DFP Announce December and January Dividends

Retrieved on: 
Monday, December 11, 2023
Banking, Professional Services, Finance, FLC, FFC, DFP, PFO, Ó Flaithbheartaigh, PFD, Security (finance)

An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.

Key Points: 
  • An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.
  • A distribution rate that is largely comprised of sources other than income may not be reflective of a fund’s performance.
  • FLC invests primarily in preferred and other income-producing securities with a primary investment objective of high current income and a secondary objective of capital appreciation.
  • DFP invests primarily in preferred and other income-producing securities with an investment objective of total return, with an emphasis on high current income.

PFD, PFO, FFC, FLC and DFP Announce November Distributions

Retrieved on: 
Thursday, October 19, 2023
Professional Services, Finance, PFD, Ó Flaithbheartaigh, PFO, FFC, DFP, FLC, Life insurance, Security (finance)

As in prior years, each fund expects to announce December and January distributions during the second week of December.

Key Points: 
  • As in prior years, each fund expects to announce December and January distributions during the second week of December.
  • FLC invests primarily in preferred and other income-producing securities with a primary investment objective of high current income and a secondary objective of capital appreciation.
  • DFP invests primarily in preferred and other income-producing securities with an investment objective of total return, with an emphasis on high current income.
  • PFD, PFO, FFC, FLC and DFP are managed by Flaherty & Crumrine Incorporated, an independent investment adviser which was founded in 1983 to specialize in the management of portfolios of preferred and related income-producing securities.

THE GORE RELIEF CLINICAL STUDY BEGINS RANDOMIZING PATIENTS TO EVALUATE PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

Retrieved on: 
Tuesday, October 17, 2023
European, Hospital, Physician, PFO, Food, Stroke, Migraine, Risk, Safety, Headache, Patient, Education, Food and Drug Administration, Use, History, Ventricular septal defect, Research, Trial of the century, Pharmaceutical industry, Medical device

FLAGSTAFF, Ariz., Oct. 17, 2023 /PRNewswire/ -- W. L. Gore & Associates (Gore) announces that patients have passed through the multi-month enhanced screening process and have begun entering the final randomization phase of the Gore RELIEF Clinical Study, an investigational study to evaluate the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) for the relief of migraine headaches utilizing the GORE® CARDIOFORM Septal Occluder, a permanently implanted device.

Key Points: 
  • The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) with the GORE® CARDIOFORM Septal Occluder for the relief of migraine headaches.
  • "The RELIEF Clinical Study investigates whether PFO closure may reduce the number of monthly migraine headache days for select patients.
  • No previous PFO closure migraine trial has yet included such clearly defined selection criteria designed to identify those patients expected to most likely respond to this potential,
    PFO-mediated mechanism," said Robert Sommer, M.D., National Principal Investigator, RELIEF Clinical Study.
  • "Clinical experiences have suggested a platelet-based connection between migraine and PFO, and there may be a correlation between PFO closure responsiveness and thienopyridine responsiveness.

NeuraSignal’s NovaGuide™ Intelligent Ultrasound System Significantly Outperforms Standard of Care for Detecting Stroke-Associated Heart Defects

Retrieved on: 
Tuesday, October 10, 2023
Patent, Diagnosis, Esophagus, PFO, Physician, Edward Hines, Acquisition, Intelligence, TCD, Brain, RLS, Risk, Heart, Safety, Travel, LOS, TEE, Recurrence, TTE, Principal, Robotics, Service, Neurology, Pathology, Veterans Health Administration, Patient, Medical imaging, Pharmaceutical industry, Stroke

LOS ANGELES, Oct. 10, 2023 (GLOBE NEWSWIRE) -- NeuraSignal, a medical technology and data company specializing in the assessment and management of brain health, today announced the publication of positive results from the BUBL clinical study (#NCT04604015) supporting the safety and superior performance of its NovaGuide Intelligent Ultrasound system in detecting Right to Left Shunt (RLS) — often due to a patent foramen ovale (PFO) — in patients with acute ischemic stroke. The data, published in Stroke, show that the NovaGuide system detected RLS that TTE missed. Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.

Key Points: 
  • The data, published in Stroke , show that the NovaGuide system detected RLS that TTE missed.
  • Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.
  • “An accurate assessment for RLS is a critical part of evaluating patients with cryptogenic ischemic stroke.
  • The standard of care for PFO screening is TTE, an ultrasound-based approach in which the ultrasound transducer is moved across the chest to create an image of the heart.

UltraNav System Enables Safer and More Cost-Effective Transseptal Procedures by Aligning Catheter and Ultrasound

Retrieved on: 
Wednesday, October 11, 2023
Hospital, Congenital heart defect, Physician, PFO, ICE, PST, Cardiology, Heart, Safety, TEE, Learning curve, Catheter, RF, FDA, Orientation, ASD, Anesthesia, Needle, DIB, TCT, Patient, Medical device, Medical imaging

SCOTTSDALE, Ariz., Oct. 11, 2023 /PRNewswire/ -- Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for use in atrial transseptal procedures and delivery of catheters, has now been successfully used in 15 human cases, at major cardiology hospitals in Arizona and Minnesota.

Key Points: 
  • The significant rise in structural transseptal heart procedures mandates the need for a safer, more accurate approach.
  • UltraNav improves the safety and accuracy of transseptal procedures by enabling better visualization of the catheter, needle, and needle tip.
  • "There's been a significant rise in structural transseptal heart procedures, which mandates the need for a safer, more accurate approach," said Dr. Nabil Dib, founder of Dib UltraNav Medical and inventor of the UltraNav Transseptal Catheter System.
  • The single-use, dual-lumen, non-steerable Dib UltraNav System intravascular catheter and handle received FDA 510(k) clearance in March 2022.

Clean Harbors Announces Second-Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 2, 2023
Energy, Recycling, Environment, Oil, Gas, Pressure, Maintenance, PFO, PFAS, Defense, Total Recordable Incident Rate, Field service management, Eastman Kodak Co. v. Image Technical Services, Inc., GAAP, Ecosystem, Clean Harbors, Government, Plant, EBITDA, Acquisition, Incineration, Department of Defense Education Activity, CLH, CFO, Growth, Veolia Environmental Services, NYSE, Economics, Gasoline, Bookkeeping, Renewable energy, Q2, SKSS, Adjustment, Maritime Industrial Services

Clean Harbors, Inc. (“Clean Harbors”) (NYSE: CLH), the leading provider of environmental and industrial services throughout North America, today announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Clean Harbors, Inc. (“Clean Harbors”) (NYSE: CLH), the leading provider of environmental and industrial services throughout North America, today announced financial results for the second quarter ended June 30, 2023.
  • “Clean Harbors delivered a strong second-quarter performance, highlighted by the continued momentum of the Environmental Services (ES) segment,” said Eric Gerstenberg, Co-Chief Executive Officer.
  • Industrial Services continues to be a meaningful contributor to our 2023 success, and we expect a healthy fall turnaround season.
  • For the third quarter of 2023, Clean Harbors expects its ES segment to continue to grow and perform well.

PFD, PFO, FFC, FLC and DFP Announce August, September and October Dividends

Retrieved on: 
Wednesday, July 19, 2023
Banking, Professional Services, Finance, FLC, Ó Flaithbheartaigh, PFO, PFD, FFC, DFP, Security (finance)

An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.

Key Points: 
  • An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.
  • A distribution rate that is largely comprised of sources other than income may not be reflective of a fund’s performance.
  • FLC invests primarily in preferred and other income-producing securities with a primary investment objective of high current income and a secondary objective of capital appreciation.
  • DFP invests primarily in preferred and other income-producing securities with an investment objective of total return, with an emphasis on high current income.

IGC Pharma to Present at LD Micro Invitational XIII

Retrieved on: 
Thursday, May 18, 2023
IGC, PFO, NYSE, Film industry, Powder metallurgy, Pharmaceutical industry

Presentation on Tuesday, June 6 at 3:00 PM PT

Key Points: 
  • Los Angeles, California--(Newsfile Corp. - May 18, 2023) - IGC Pharma, Inc. (NYSE American: IGC) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California June 6th-8th, 2023.
  • The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.
  • IGC Pharma is scheduled to present on Tuesday, June 6 at 3:00 pm PT.
  • Ram Mukunda, CEO, and Claudia Grimaldi, PFO, will be leading the presentation.

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
Immortalised cell line, Process, PFO, Diabetes, Half-life, Biotechnology, Clinical trial, Haemophilia, Traffic barrier, Research, Cell, Glycogen storage disease, Patient, Conditional sentence, Eli Lilly and Company, NHP, B cell, Therapy, IND, D, Pharmaceutical industry, Vaccine, Lilly

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2023 as well as certain other business highlights.

Key Points: 
  • In the first quarter of 2023, Sigilon decreased its external spend relating to the mucopolysaccharidosis type 1 (MPS-1) program to preserve capital.
  • R&D Expenses: Research and development expenses were $7.8 million for the first quarter of 2023 compared to $11.6 million for the first quarter of 2022.
  • G&A Expenses: General and administrative expenses were $4.3 million for the first quarter of 2023 compared to $5.0 million for the first quarter of 2022.
  • Net Loss: Net loss was $7.4 million for the first quarter of 2023 compared to $13.9 million for the first quarter of 2022.